
|Videos|September 10, 2015
Biosimilars Poised to Impact Specialty Pharmacy
Author(s)Davy James, Managing Editor
Amy Grogg, PharmD, senior vice president of Strategy and Commercialization at AmerisourceBergen Specialty Group, discusses the projected ramifications from the launch of biosimilars in the United States.
Advertisement
Amy Grogg, PharmD, senior vice president of Strategy and Commercialization at AmerisourceBergen Specialty Group, discusses the projected ramifications from the launch of biosimilars in the United States.
This video was recorded courtesy of Armada Health Care at the 2015 Armada Specialty Pharmacy Summit in Las Vegas, Nevada.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Beyond Injections: Orforglipron and the Future of Oral GLP-1 Receptor Agonist Therapy
2
Federal Health Officials Scale Back Number of Recommended Vaccines for Children
3
Toothpaste Tablets Are Gaining Popularity—Here’s Where Pharmacists Fit In
4
GoodRx Expands Access to Oral GLP-1 Therapy With Semaglutide Pill Cash Pricing
5













































































































































































































